Press release
Rare Kidney Diseases Market Exclusive Report on Current Trends and Future Insights
The Rare Kidney Diseases Market Size is valued at 2528.9 Million in 2022 and is predicted to reach 5738.7 Million by the year 2031 at a 9.7% CAGR during the forecast period for 2023-2031.
Get A Free Report Brochure: https://www.insightaceanalytic.com/request-sample/1414
Rare kidney diseases (RKD) encompass approximately 150 distinct conditions. In the United States (US) and Europe, the prevalence of rare kidney diseases is estimated to range between 60 and 80 per 100,000 cases/individuals.
Approximately one-third of adults with diabetes and one-fifth of adults with hypertension may have kidney disease. Kidney diseases kill more people than breast and prostate cancers combined (NVS 2021 report of 2018 data). Kidney disease patients are five to ten times more probable to die prematurely than to develop kidney failure with replacement therapy (KFRT). It's important to note that after the COVID-19 pandemic started, it became even harder to treat people with rare kidney diseases.
This is mainly because most current treatments for these conditions require patients to go to the hospital or medical center often. As a result, the death rate for sick people during the pandemic went up by 30%. This rise in death rates has forced people in the pharmaceutical industry to do the research they need to find new drugs that can effectively treat rare kidney diseases.
Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1414
Multiple important factors are propelling the market expansion for rare kidney diseases. The collaborative interactions between clinicians, patients, industry representatives, regulatory agents, and government agencies contribute to the increase in the demand for complex illnesses due to diagnostic and therapeutic advances. In addition, the increased use of next-generation sequencing techniques is anticipated to improve diagnostic accuracy for rare renal diseases, contribute to the elucidation of molecular disease mechanisms, facilitate genetic counselling, and offer opportunities for carrier testing. Renal replacement therapy innovations and increased accessibility allow patients to live longer at the expense of their quality of life.
Therapeutic advances in rare kidney diseases have been hampered by unresolved genetic defects, a lack of biomarkers to track disease progression, heterogeneous clinical phenotypes, and obsolete diagnostic classifications that do not reflect underlying pathophysiological mechanisms. Slow drug approvals and detailed studies will also restrain market expansion.
As a result of its rapid clinical advancements and research into kidney disease treatments, North America will dominate and lead the global market for rare kidney diseases during the projected period.
The key market players are GlaxoSmithKline, Recordati Rare Diseases, Amicus Therapeutics, Calliditas Therapeutics, Alexion Pharmaceuticals (A subsidiary of AstraZeneca), Travere Therapeutics, Aurinia Pharmaceutical, Advicenne, Protalix Biotherapeutics, AstraZeneca, Chinook Therapeutics, Reata Pharmaceuticals, Roche, Novartis Pharmaceuticals, Merk & co., Apellis Pharmaceuticals, Omeros Corporation, Lonza, and Other Prominent Players.
Get Specific Chapter/Information From The Report: https://www.insightaceanalytic.com/customisation/1414
Key Developments in The Market:
• In Aug 2022, CSL Vifor and Travere Therapeutics announced that the European Medicines Agency (EMA) has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the treatment of a rare kidney disorder IgAN, and a leading cause of end-stage kidney disease (ESKD).
• In Dec 2021, The FDA approved the first drug to reduce urine protein levels in IgA nephropathy, a rare kidney disease. Tarpeyo (budesonide) delayed-release capsules have been granted accelerated approval by the FDA to minimise proteinuria (increased protein levels in the urine) in adults with primary immunoglobulin A (IgA) nephropathy who are at risk of rapid disease progression.
• In Sept 2021, Allarity Therapeutics and Lonza agreed to collaborate on developing and manufacturing dovitinib, Allarity's renal cell carcinoma candidate therapy. The agreement called for the start of dovitinib manufacturing in 2022 to meet Allarity's projected needs for bringing dovitinib to market after regulatory approvals.
• In June 2021, Novartis announced new Phase II interim data for iptacopan in the rare kidney disease C3 glomerulopathy (C3G). Iptacopan is being developed for a number of (CDRDs) complement-driven renal diseases, including C3Gand (IgAN) IgA nephropathy, the blood disorder paroxysmal nocturnal hemoglobinuria (PNH), with the goal of addressing a vital driver of these diseases.
Market Segmentation
Global Rare Kidney Diseases Market, by Target Indication, 2022-2030 (Value US$ Mn)
• IgA Nephropathy
• Lupus Nephritis
• Focal Segmental Glomerular Sclerosis
• Membranous Nephropathy
• C3 Glomerulopathy
• Cystinosis
• Dense Deposit Disease
• Distal Renal Tubular Acidosis
• Fabry Disease
• Refractory Gout
• Atypical Hemolytic Uremic Syndrome
• Others
Global Rare Kidney Diseases Market, by Type of Molecule, 2022-2030 (Value US$ Mn)
• Small Molecules
• Biologics
o Monoclonal Antibody
o Hormone
o Recombinant Protein
o Others
Global Rare Kidney Diseases Market, by Route of Administration, 2022-2030 (Value US$ Mn)
• Oral
• Intravenous
• Subcutaneous
• Others
Global Rare Kidney Diseases Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa
For More Information: https://www.insightaceanalytic.com/report/global-rare-kidney-diseases-market-/1414
Other Related Reports Published by InsightAce Analytic:
Global Biosimilar Monoclonal Antibodies Market
Global Dialysis Equipment Market
Global Therapeutic Proteins and Oral Vaccines Market
Corporate Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
loaction icon
Sales Office (U.S.) :
344 Grove St Unit #967 Jersey City, NJ 07302
email iconinfo@insightaceanalytic.com
call icon
North America:
+1 551 226 6109
Asia:
+91 79 72967118
Contact Us:
Dhanraj Zurange
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rare Kidney Diseases Market Exclusive Report on Current Trends and Future Insights here
News-ID: 3385063 • Views: …
More Releases from Insightace analytic
Digital Pathology Market Report- Expansive Coverage on the Profit Sources
InsightAce Analytic announces the release of a market assessment report on the "Global Digital Pathology Market Size, Share & Trends Analysis Report By Product (Artificial Intelligence, Scanner, Software, Storage), Type (Human, Veterinary), Application (Teleconsultation, Training, Disease Diagnosis, Drug Discovery), End User (Pharma, Academia, Hospitals)- Market Outlook And Industry Analysis 2031"
The global digital pathology market is estimated to reach over USD 2731.95 million by 2031, exhibiting a CAGR of 12.91%…
Digital Health Market Future Trends and Scope Analysis Report
Digital Health Market Size, Share & Trends Analysis Report By Technology (Tele-healthcare, mHealth, Healthcare Analytics, Digital Health Systems), By Component (Software, Hardware, Services), By Region, And Segment Forecasts, 2024-2031
"Digital Health Market" in terms of revenue was estimated to be worth $248.58 billion in 2023 and is poised to reach $1,004.03 billion by 2031, growing at a CAGR of 19.56% from 2023 to 2031, according to a new report by…
Digital Diabetes Management Market Report on the Untapped Growth Opportunities i …
InsightAce Analytic announces the release of a market assessment report on the "Global Digital Diabetes Management Market - (By Devices (Smart Glucose Meters, Continuous Glucose Monitoring Systems, And Smart Insulin Pens, Smart Insulin Pumps/ Closed-Loop Pumps & Smart Insulin Patches), Application (Diabetes & Blood Glucose Tracking Apps, Obesity & Diet Management Apps), Data Management Software & Platforms And Services), By Device Type (Handheld And Wearable Devices), By End-User(Self/Home Healthcare, Hospitals…
Data Center Liquid Cooling Market Exclusive Trends Analysis with Forecast to 203 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Data Center Liquid Cooling Market Size, Share & Trends Analysis Report By End-User Industry (Financial Services And Insurance (BFSI), Banking, IT And Telecom, Government And Public Sector, Manufacturing, Healthcare, Retail), Data Center (Hyperscale, Colocation, Enterprise) And Solution (Indirect & Direct Cooling)- Market Outlook And Industry Analysis 2031"
The Global Data Center Liquid Cooling Market is estimated…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
